Agentix Corp. Reports Net Loss of $78,595 for Quarter Ended December 31, 2025

Agentix Corp. reported its financial results for the three and nine months ended December 31, 2025, revealing a net loss of $78,595 for the quarter and $408,526 for the nine-month period. This represents an improvement compared to the same periods in 2024, where the company recorded a net loss of $143,894 for the quarter and $385,280 for the nine months. Total operating expenses decreased to $67,463 for the quarter, down from $96,815 in the prior year, primarily due to reduced professional fees and research and development costs. The company’s accumulated deficit increased to $6,930,054 as of December 31, 2025, compared to $6,521,528 at the end of the previous fiscal year.

In terms of liquidity, Agentix Corp. reported cash and cash equivalents of $6,396 as of December 31, 2025, a slight increase from $4,477 at the end of the previous quarter. However, the company continues to face significant financial challenges, with total current liabilities rising to $3,504,396 from $3,204,523 in the prior period. The increase in liabilities was driven by higher accounts payable and accrued expenses, indicating ongoing operational pressures. The company’s total stockholders' deficit also widened to $3,498,000 from $3,104,249, reflecting the ongoing losses and financial strain.

Strategically, Agentix Corp. is focused on developing therapeutic agents for metabolic diseases, including Type 2 diabetes and obesity. The company has not reported any significant acquisitions or product launches during this period, but it continues to work on its clinical research initiatives. The filing indicates that the company is actively seeking to generate sufficient revenue and may require additional financing to support its operations. The management has expressed a commitment to implementing its business plan, although the ability to continue as a going concern remains uncertain due to the current cash position and operational losses.

Operationally, Agentix Corp. has maintained a consistent employee headcount of 40,066,951 shares outstanding throughout the reporting periods. The company has not disclosed specific customer counts or user statistics, but it is evident that the focus remains on advancing its research and development efforts. The filing notes that the company is navigating a challenging economic environment, which could impact its market opportunities and overall performance.

Looking ahead, Agentix Corp. acknowledges the need for further funding to sustain its operations and continue its development efforts. The management's forward-looking statements highlight the potential for future growth, contingent upon successful execution of its business strategies and the ability to secure additional financing. However, the company cautions that actual results may differ materially from these projections due to various factors, including market conditions and competition.